Development and evaluation of a novel nebulized dihydromyricetin formulation: enhanced pulmonary delivery and pharmacokinetic properties.

ABSTRACT:

Background

Respiratory diseases are a major global health burden, and inhalation therapy offers efficient pulmonary targeting and therapeutic effectiveness. Dihydromyricetin (DMY), a natural flavonoid with anti-inflammatory and antiviral activities, shows limited clinical application due to poor solubility, instability, and low oral bioavailability caused by extensive first-pass metabolism.

Methods

A nebulized inhalation formulation of DMY was developed to enhance solubility, stability, and bioavailability. Pharmacokinetics were evaluated in rats following inhalation and oral administration. Safety was assessed through pulmonary function testing and histological examination of major organs.

Results

Inhalation delivery significantly improved DMY bioavailability in both

SUBMITTER: Xu K 

PROVIDER: S-EPMC12706889 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature